Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement

Dow Jones

03/16

By Adriano Marchese

Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement.

Shares traded 30% higher ahead of the morning bell at $4.26.

The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said.

The company aims to file an investigational new drug application for its lead candidate by mid-2027.

Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share.

The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share.

The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 16, 2026 07:17 ET (11:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2619245752"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619245752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619245752?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619245752","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n</p>\n<p>\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n</p>\n<p>\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n</p>\n<p>\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n</p>\n<p>\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n</p>\n<p>\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-03-16 19:17</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n</p>\n<p>\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n</p>\n<p>\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n</p>\n<p>\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n</p>\n<p>\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n</p>\n<p>\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619245752","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619245752","pubTimestamp":1773659820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement.Shares traded 30% higher ahead of the morning bell at $4.26.The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said.The company aims to file an investigational new drug application for its lead candidate by mid-2027.Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share.The stock has performed well so far in 2026, rising 55% since t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ABOS":"Acumen Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Acumen Pharmaceuticals因积极的阿尔茨海默病药物数据而股价上涨，私募3580万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n\n\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n\n\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n\n\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n\n\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n\n\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n\n\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 07:17 ET (11:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}